Drug Profile
Research programme: chimeric antigen receptor macrophages - Carisma Therapeutics
Alternative Names: CAR Macrophage Cellular Immunotherapy - Carisma Therapeutics; CAR-M cell therapy - Carisma TherapeuticsLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Carisma Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
- Research Haematological malignancies
Most Recent Events
- 31 Oct 2023 Research programme, Chimeric antigen receptor macrophages is still in preclinical development in Solid-tumours in USA (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 22 Apr 2021 Early research in Haematological malignancies in USA (Parenteral)